Form 4: Disc Medicine Director White Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director William Richard White exercised stock options and sold shares of Disc Medicine, Inc. under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On June 3, 2024, William Richard White, a director of Disc Medicine, Inc., engaged in multiple transactions involving the company's common stock.
- White exercised stock options to acquire 1,756 shares at $2.65 and 201 shares at $9.86.
- He then sold 107 shares at an average price of $35.1469, 1,755 shares at an average price of $36.102, and 95 shares at an average price of $36.7208.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 13, 2023.
- Following these transactions, White directly owns 0 shares of Disc Medicine, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily indicate a change in the director's view of the company's prospects. However, any insider selling can create some uncertainty.
Positives
- The transactions were executed under a pre-existing Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The sale of shares by a director could be perceived negatively by some investors, although it is part of a pre-arranged plan.
Risks
- While the 10b5-1 plan provides some protection, significant sales by insiders can still create negative market sentiment.
Industry Context
Executive compensation often includes stock options, and sales under 10b5-1 plans are a common way for executives to manage their personal finances while avoiding insider trading accusations.
Comparison to Industry Standards
- It's common for directors and officers to have stock option grants as part of their compensation packages.
- The vesting schedules described are fairly standard, with quarterly or monthly vesting over several years.
- Rule 10b5-1 plans are widely used by corporate insiders to sell shares in a predetermined manner.
Stakeholder Impact
- Shareholders may have mixed reactions, as insider sales can sometimes be perceived negatively, even if pre-planned.
- The impact on other stakeholders is likely minimal, as these are routine transactions.
Key Dates
| Date | Description |
|---|---|
| 2020-11-27 | Start date for vesting of options acquired at $2.65 in 16 equal quarterly installments. |
| 2021-09-01 | Start date for vesting of options acquired at $9.86 in 48 equal monthly installments. |
| 2023-12-13 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-06-03 | Date of the reported transactions (option exercises and share sales). |
| 2024-06-05 | Date of signature of the Form 4 filing. |
| 2030-11-26 | Expiration date for options acquired at $2.65. |
| 2031-09-13 | Expiration date for options acquired at $9.86. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.